Literature DB >> 28064235

Outcomes in Patients with pT1-T2, pN0-N1 Breast Cancer After Conservative Surgery and Whole-breast Radiotherapy.

Marianna Trignani1, Clelia DI Carlo1, Carmen Cefalogli1, Marianna Nuzzo1, Lucia Anna Ursini1, Luciana Caravatta1, Francesca Perrotti1, Marta DI Nicola2, Ambra Pamio3, Domenico Genovesi4.   

Abstract

AIM: To evaluate locoregional recurrence, overall survival, disease-free survival and prognostic influence of the number of positive lymph nodes and other variables in breast cancer treatment. PATIENTS AND METHODS: A total of 377 patients with pT1-T2, pN0-N1 invasive breast carcinoma treated from 2005 to 2013 were retrospectively evaluated. Patients underwent conservative surgery followed by whole-breast radiotherapy. Clavicular region irradiation was not performed.
RESULTS: With a median follow-up of 4 years, locoregional recurrence rate was 3.4% (nodal recurrence=1.06%). Expression of progesterone receptors was significantly associated with better disease-free survival, tumor size (T>2 cm) with poorer disease-free survival, locoregional recurrence and poorer overall survival; the presence of three nodal metastases was related to significantly poorer overall survival (p=0.024).
CONCLUSION: Whole-breast adjuvant radiotherapy without nodal irradiation after breast-conserving surgery led to low rate of locoregional recurrence and high rates of overall survival and disease-free survival in patients with pT1-T2 pN0-N1 breast cancer. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Breast cancer; adjuvant radiotherapy; conservative surgery; pN0-N1; pT1-T2

Mesh:

Year:  2017        PMID: 28064235      PMCID: PMC5354142          DOI: 10.21873/invivo.11039

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  18 in total

1.  The clinical value of adjuvant radiotherapy in patients with early stage breast cancer with 1 to 3 positive lymph nodes after mastectomy.

Authors:  San-Gang Wu; Zhen-Yu He; Feng-Yan Li; Jun-Jie Wang; Jun Guo; Qin Lin; Xun-Xing Guan
Journal:  Chin J Cancer       Date:  2010-07

2.  The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.

Authors:  Pauline T Truong; Eric Berthelet; Junella Lee; Hosam A Kader; Ivo A Olivotto
Journal:  Cancer       Date:  2005-05-15       Impact factor: 6.860

3.  Supraclavicular nodal failure in patients with one to three positive axillary lymph nodes treated with breast conserving surgery and breast irradiation, without supraclavicular node radiation.

Authors:  Shruthi G Reddy; Krystyna D Kiel
Journal:  Breast J       Date:  2007 Jan-Feb       Impact factor: 2.431

4.  Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment.

Authors:  Lorenzo Livi; Fabiola Paiar; Calogero Saieva; Silvia Scoccianti; Dora Dicosmo; Simona Borghesi; Benedetta Agresti; Fabiano Nosi; Lorenzo Orzalesi; Roberto Santini; Raffaella Barca; Giampaolo P Biti
Journal:  Radiother Oncol       Date:  2006-12-22       Impact factor: 6.280

5.  Regional Nodal Irradiation in Early-Stage Breast Cancer.

Authors:  Timothy J Whelan; Ivo A Olivotto; Wendy R Parulekar; Ida Ackerman; Boon H Chua; Abdenour Nabid; Katherine A Vallis; Julia R White; Pierre Rousseau; Andre Fortin; Lori J Pierce; Lee Manchul; Susan Chafe; Maureen C Nolan; Peter Craighead; Julie Bowen; David R McCready; Kathleen I Pritchard; Karen Gelmon; Yvonne Murray; Judy-Anne W Chapman; Bingshu E Chen; Mark N Levine
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

6.  Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.

Authors:  Philip M Poortmans; Sandra Collette; Carine Kirkove; Erik Van Limbergen; Volker Budach; Henk Struikmans; Laurence Collette; Alain Fourquet; Philippe Maingon; Mariacarla Valli; Karin De Winter; Simone Marnitz; Isabelle Barillot; Luciano Scandolaro; Ernest Vonk; Carla Rodenhuis; Hugo Marsiglia; Nicola Weidner; Geertjan van Tienhoven; Christoph Glanzmann; Abraham Kuten; Rodrigo Arriagada; Harry Bartelink; Walter Van den Bogaert
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

7.  Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status.

Authors:  Po Sheng Yang; Chi Ming Chen; Mei Ching Liu; Jer Min Jian; Cheng Fang Horng; Ming Jiung Liu; Ben Long Yu; Ming Yuan Lee; Chin Wen Chi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-07-04       Impact factor: 7.038

8.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

Authors:  Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

9.  Outcome after conservative surgery and breast irradiation in 5,717 patients with breast cancer: implications for supraclavicular nodal irradiation.

Authors:  Lorenzo Livi; Vieri Scotti; Calogero Saieva; Icro Meattini; Beatrice Detti; Gabriele Simontacchi; Carla Deluca Cardillo; Fabiola Paiar; Monica Mangoni; Livia Marrazzo; Benedetta Agresti; Luigi Cataliotti; Simonetta Bianchi; Giampaolo Biti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-18       Impact factor: 7.038

Review 10.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.

Authors:  S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto
Journal:  Lancet       Date:  2011-10-19       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.